IDOV-Safe leverages an unusually high extracellular enveloped virion proportion (~60%) to support true intravenous oncolytic virus delivery despite circulating neutralizing proteins. The phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results